SG11201401648RA - Methods and compositions for neuroprotection - Google Patents

Methods and compositions for neuroprotection

Info

Publication number
SG11201401648RA
SG11201401648RA SG11201401648RA SG11201401648RA SG11201401648RA SG 11201401648R A SG11201401648R A SG 11201401648RA SG 11201401648R A SG11201401648R A SG 11201401648RA SG 11201401648R A SG11201401648R A SG 11201401648RA SG 11201401648R A SG11201401648R A SG 11201401648RA
Authority
SG
Singapore
Prior art keywords
neuroprotection
compositions
methods
Prior art date
Application number
SG11201401648RA
Inventor
Elena Feinstein
Original Assignee
Quark Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US201161554982P priority Critical
Priority to US201261663627P priority
Application filed by Quark Pharmaceuticals Inc filed Critical Quark Pharmaceuticals Inc
Priority to PCT/US2012/062894 priority patent/WO2013067076A2/en
Publication of SG11201401648RA publication Critical patent/SG11201401648RA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0046Ear
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22Cysteine endopeptidases (3.4.22)
    • C12Y304/22017Calpain (3.4.22.17)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22Cysteine endopeptidases (3.4.22)
    • C12Y304/22055Caspase-2 (3.4.22.55)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y306/00Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/03Hydrolases acting on acid anhydrides (3.6) acting on acid anhydrides; catalysing transmembrane movement of substances (3.6.3)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y306/00Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/05Hydrolases acting on acid anhydrides (3.6) acting on GTP; involved in cellular and subcellular movement (3.6.5)
    • C12Y306/05002Small monomeric GTPase (3.6.5.2)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering N.A.
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • C12N2310/3212'-O-R Modification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications
    • C12N2320/32Special delivery means, e.g. tissue-specific
SG11201401648RA 2011-11-03 2012-11-01 Methods and compositions for neuroprotection SG11201401648RA (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US201161554982P true 2011-11-03 2011-11-03
US201261663627P true 2012-06-25 2012-06-25
PCT/US2012/062894 WO2013067076A2 (en) 2011-11-03 2012-11-01 Methods and compositions for neuroprotection

Publications (1)

Publication Number Publication Date
SG11201401648RA true SG11201401648RA (en) 2014-05-29

Family

ID=47436166

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201401648RA SG11201401648RA (en) 2011-11-03 2012-11-01 Methods and compositions for neuroprotection

Country Status (12)

Country Link
US (2) US9422560B2 (en)
EP (1) EP2773758B1 (en)
JP (1) JP6118331B2 (en)
CN (1) CN103917647A (en)
AU (1) AU2012332517B9 (en)
BR (1) BR112014010769A2 (en)
CA (1) CA2851296A1 (en)
IL (1) IL232085A (en)
MX (1) MX356814B (en)
SG (1) SG11201401648RA (en)
WO (1) WO2013067076A2 (en)
ZA (1) ZA201403281B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201691215A1 (en) * 2013-12-12 2016-11-30 Элнилэм Фармасьютикалз, Инк. COMPOSITION ON THE BASIS iRNA To complement components and methods of use thereof

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (en) 1970-11-10 1977-09-15 Organon Nv Method for the detection and determination of laagmoleculire compounds and of proteins that can specifically bind these compounds, as well as the test pack.
NL154599B (en) 1970-12-28 1977-09-15 Organon Nv Method for the detection and determination of specific binding proteins and their corresponding bindable substances, as well as the test pack.
NL154600B (en) 1971-02-10 1977-09-15 Organon Nv Method for the detection and determination of specific binding proteins and their corresponding bindable substances.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (en) 1972-05-11 1983-06-01 Akzo Nv Method for the detection and determination of haptens, as well as test packs.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202B1 (en) 1985-03-28 1990-11-27 Cetus Corp
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5270030A (en) 1988-12-29 1993-12-14 Bio-Technology General Corp. Fibrin binding domain polypeptide and method of producing
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5378825A (en) 1990-07-27 1995-01-03 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs
DE69232032T3 (en) 1991-12-24 2012-09-13 Isis Pharmaceutical, Inc. Antisense oligonucleotides
JPH08500481A (en) 1992-05-11 1996-01-23 リボザイム・ファーマシューティカルズ・インコーポレーテッド Methods and agents for inhibiting the replication of the virus
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US5998203A (en) 1996-04-16 1999-12-07 Ribozyme Pharmaceuticals, Inc. Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
JP3756313B2 (en) 1997-03-07 2006-03-15 武 今西 New bicyclo nucleosides and oligonucleotide analogues
US6251666B1 (en) 1997-03-31 2001-06-26 Ribozyme Pharmaceuticals, Inc. Nucleic acid catalysts comprising L-nucleotide analogs
TW589189B (en) 1997-08-04 2004-06-01 Scras Kit containing at least one double-stranded RNA combined with at least one anti-viral agent for therapeutic use in the treatment of a viral disease, notably of viral hepatitis
WO1999014226A2 (en) 1997-09-12 1999-03-25 Exiqon A/S Bi- and tri-cyclic nucleoside, nucleotide and oligonucleotide analogues
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AR020078A1 (en) 1998-05-26 2002-04-10 Syngenta Participations Ag Method for altering the expression of a target gene in a plant cell
GB9827152D0 (en) 1998-07-03 1999-02-03 Devgen Nv Characterisation of gene function using double stranded rna inhibition
AU776150B2 (en) 1999-01-28 2004-08-26 Medical College Of Georgia Research Institute, Inc. Composition and method for (in vivo) and (in vitro) attenuation of gene expression using double stranded RNA
DE19956568A1 (en) 1999-01-30 2000-08-17 Roland Kreutzer Method and medicament for the inhibition of expression of a given gene
CN1273478C (en) 1999-02-12 2006-09-06 三共株式会社 Novel nucleosides and oligonucleotide analogues
JP2003516124A (en) 1999-10-15 2003-05-13 カーネギー インスティテューション オブ ワシントン rna interference pathway genes as a means of genetic interference targeting
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
KR20080023768A (en) 2000-03-30 2008-03-14 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. Rna sequence-specific mediators of rna interference
US20040019001A1 (en) 2002-02-20 2004-01-29 Mcswiggen James A. RNA interference mediated inhibition of protein typrosine phosphatase-1B (PTP-1B) gene expression using short interfering RNA
US20050032067A1 (en) 2002-11-05 2005-02-10 Prakash Thazha P. Non-phosphorous-linked oligomeric compounds and their use in gene modulation
EP1606406B2 (en) 2003-03-21 2013-11-27 Santaris Pharma A/S SHORT INTERFERING RNA (siRNA) ANALOGUES
EP1602926A1 (en) 2004-06-04 2005-12-07 University of Geneva Novel means and methods for the treatment of hearing loss and phantom hearing
EP1791568B1 (en) 2004-08-16 2012-08-15 Quark Pharmaceuticals, Inc. Therapeutic uses of inhibitors of rtp801
WO2006047842A2 (en) 2004-11-08 2006-05-11 K.U. Leuven Research And Development Modified nucleosides for rna interference
US7825099B2 (en) 2006-01-20 2010-11-02 Quark Pharmaceuticals, Inc. Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes
US8362229B2 (en) 2006-02-08 2013-01-29 Quark Pharmaceuticals, Inc. Tandem siRNAS
JP2010507387A (en) 2006-10-25 2010-03-11 クアーク・ファーマスーティカルス、インコーポレイテッドQuark Pharmaceuticals,Inc. New siRNA and methods of use thereof
EP2137205A2 (en) * 2007-02-26 2009-12-30 Quark Pharmaceuticals, Inc. Inhibitors of rtp801 and their use in disease treatment
ES2474176T3 (en) 2007-06-27 2014-07-08 Quark Pharmaceuticals, Inc. Compositions and methods for inhibiting gene expression pro-apoptticos
WO2009044392A2 (en) 2007-10-03 2009-04-09 Quark Pharmaceuticals, Inc. Novel sirna structures
EP2242854A4 (en) 2008-01-15 2012-08-15 Quark Pharmaceuticals Inc Sirna compounds and methods of use thereof
BRPI0909270A2 (en) 2008-03-20 2015-08-11 Quark Pharmaceuticals Inc siRNA compounds for inhibiting rtp801
US8431692B2 (en) * 2008-06-06 2013-04-30 Quark Pharmaceuticals, Inc. Compositions and methods for treatment of ear disorders
JP5592892B2 (en) * 2008-10-22 2014-09-17 クォーク ファーマシューティカルズ インコーポレーティッドQuark Pharmaceuticals,Inc. Method for the treatment of eye disorders
EP2504435A1 (en) 2009-11-26 2012-10-03 Quark Pharmaceuticals, Inc. Sirna compounds comprising terminal substitutions
EP2510098B1 (en) 2009-12-09 2015-02-11 Quark Pharmaceuticals, Inc. Methods and compositions for treating diseases, disorders or injury of the cns
WO2011084193A1 (en) 2010-01-07 2011-07-14 Quark Pharmaceuticals, Inc. Oligonucleotide compounds comprising non-nucleotide overhangs
KR101553753B1 (en) 2010-06-24 2015-09-16 쿠아크 파마수티칼스 인코퍼레이티드 Double stranded rna compounds to rhoa and use thereof

Also Published As

Publication number Publication date
ZA201403281B (en) 2015-08-26
WO2013067076A3 (en) 2013-07-04
MX356814B (en) 2018-06-13
US20150031746A1 (en) 2015-01-29
JP2015501634A (en) 2015-01-19
AU2012332517A1 (en) 2014-04-24
JP6118331B2 (en) 2017-04-19
EP2773758B1 (en) 2017-06-07
EP2773758A2 (en) 2014-09-10
WO2013067076A2 (en) 2013-05-10
AU2012332517B2 (en) 2017-04-06
AU2012332517B9 (en) 2017-08-10
CN103917647A (en) 2014-07-09
US9738896B2 (en) 2017-08-22
BR112014010769A2 (en) 2018-08-07
IL232085A (en) 2018-04-30
IL232085D0 (en) 2014-05-28
CA2851296A1 (en) 2013-05-10
US9422560B2 (en) 2016-08-23
KR20140091683A (en) 2014-07-22
US20160362695A1 (en) 2016-12-15
MX2014005424A (en) 2014-10-17

Similar Documents

Publication Publication Date Title
TWI520737B (en) Certain amino-pyrimidines, compositions thereof, and methods for their use
EP2609733A4 (en) Techniques for object based operations
EP2721179A4 (en) Biomarker compositions and methods
SI2734522T1 (en) 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk-inhibitors
EP2742154A4 (en) Biomarker compositions and methods
EP2675909A4 (en) Clucosyl stevia composition
SG11201502598SA (en) Compositions and methods for immunotherapy
EP2608762A4 (en) Compositions and methods for targeted thermomodulation
EP2758441A4 (en) Modified polyethylene compositions
HUE036336T2 (en) Compositions
EP2739857A4 (en) Blower
GB201010196D0 (en) Methods
PT2707224T (en) Polymer compositions and methods
TWI501963B (en) Certain amino-pyridazines, compositions thereof, and methods for their use
GB201006699D0 (en) Composition
EP2756437A4 (en) Device-tailored whitelists
GB201113388D0 (en) Fuel compositions
EP2836212A4 (en) Novel compositions and methods
EP2663635A4 (en) Microbial compositions and methods
EP2703444A4 (en) Rubber composition
HK1231378A1 (en) Composition for treating hcv hcv
IL230470D0 (en) Curable compositions and membranes
EP2560488A4 (en) Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
IL227514A (en) Rebaudioside-mogroside v blends
IL230469D0 (en) Curable compositions and membranes